Earnings due 17 Feb 2026: AGSTRA.NS AGS Transact Technologies (NSE) margin test

AGSTRA.NS stock trades at INR 3.74 in pre-market on 17 Feb 2026 as investors prepare for the company’s earnings release. Volume stands at 191,582 shares versus an average of 189,360. Key near-term questions are revenue growth, margin recovery and contract wins in ATM and cash management services. We assess financial ratios, technical signals and Meyka AI’s model-based forecast to highlight outcomes market participants should watch on the NSE.

AGSTRA.NS stock: pre-earnings snapshot

AGSTRA.NS stock is quoted at INR 3.74, down 2.35% from the previous close of INR 3.83. Day range is INR 3.70 to INR 3.83 and year range is INR 3.66 to INR 30.15. Market capitalisation is INR 479,116,455.00 and shares outstanding total 128,106,004. The company reports EPS -13.96 and PE -0.27, signalling persistent losses despite a high gross margin.

Earnings expectations and key drivers for AGSTRA.NS stock

Earnings are scheduled for 17 Feb 2026 and analysts will focus on revenue from Payment Solutions and cash management margins. Watch for updates on ATM outsourcing contracts, CRM deployments and service-margin trends. Management commentary on client renewals and cost controls will be the main catalyst for intraday moves on the NSE.

AGSTRA.NS analysis: financials and valuation

AGS Transact shows book value per share INR 44.01 while the stock trades at a price-to-book 0.08. Price-to-sales is 0.09, and operating profit margin is negative at -31.57%. Interest coverage is -2.39, with reported cash-flow per share effectively zero. The valuation reflects asset backing but persistent profit and cash-flow weakness, creating a high-risk, deep-value profile.

AGSTRA.NS stock technicals and trading signals

Short-term technicals are weak: RSI 41.52, MACD -0.07, and ADX 12.49 indicating no clear trend. Bollinger middle band is INR 4.16 and the stock sits below this level. On-balance volume is negative and CCI at -183.61 shows oversold conditions. Near-term support lies at the year low INR 3.66 and immediate resistance near INR 4.16.

Meyka AI grade and AGSTRA.NS stock forecast

Meyka AI rates AGSTRA.NS with a score of 62.11 out of 100 (Grade: B, Suggestion: HOLD). This grade factors S&P 500 comparison, sector performance, financial growth, key metrics and analyst consensus. Meyka AI’s forecast model projects a 12-month fair value of INR 9.00, implying upside of 140.64% from the current INR 3.74. Conservatively, short-term price targets include INR 5.00 (base) and INR 2.50 (bear). Forecasts are model-based projections and not guarantees.

Risks and catalysts affecting AGSTRA.NS stock outlook

Key risks include client concentration, weak operating cash flow, and slim interest coverage. Regulatory changes in ATM outsourcing and slower merchant volumes are downside risks. Catalysts include major contract renewals, cost rationalisation and service-margin improvements. Sector headwinds for Technology stocks in India also matter to market sentiment.

Final Thoughts

AGSTRA.NS stock trades at INR 3.74 entering the 17 Feb 2026 earnings report, leaving traders to weigh near-term downside versus deep-value upside. The company posts EPS -13.96 and a price-to-book 0.08, showing strong tangible assets but weak profits. Short-term technicals point to oversold conditions while operational metrics require improvement. Meyka AI’s model projects a 12-month fair value of INR 9.00, an implied upside of 140.64% from current levels, but we flag high execution risk. For active traders, manage risk around support at INR 3.66 and resistance near INR 4.16. Long-term value investors must see consistent margin recovery before increasing exposure. Use Meyka AI’s market analysis tools and watch the earnings call for explicit guidance on contracts and cash flow.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.